BANK VONTOBEL/PUT/BIOGEN IDEC/260/0.01/21.06.24 | Delayed Deutsche Boerse AG 05:11:31 03/06/2024 pm IST | ||
| 0.32 EUR | -3.03% |
|
| 1 month | -19.51% | ||
| 3 months | -10.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.32 | -3.03% |
| 31/24/31 | 0.33 | -15.38% |
| 30/24/30 | 0.39 | -4.88% |
| 29/24/29 | 0.41 | +5.13% |
| 28/24/28 | 0.39 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 05:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU9CS1 |
| ISIN | DE000VU9CS14 |
| Date issued | 03/07/2023 |
| Strike | 260 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 100 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.66 € |
|---|---|
| Lowest since issue | 0.168 € |
| Spread | 0.02 € |
| Spread % | 5.88% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
